Royal Sense Ltd544143Corporate

Medical Equipment & Supplies Latest results: Mar 2026 6 quarters of data

₹87.00

MCap ₹47 Cr · P/E 15.5

Royal Sense Ltd — Stock analysis & AI research Royal Sense Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹17 Cr

Sales · Mar 2026

+2.5% YoY

₹2 Cr

Operating Profit · Mar 2026

+17.0% YoY

11.4%

OPM % · Mar 2026

+14.0% YoY

₹1 Cr

Net Profit · Mar 2026

-5.4% YoY

₹1.98

EPS · Mar 2026

-12.0% YoY

📝 Royal Sense Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Royal Sense Ltd reported revenue of ₹17 crore for the quarter ended March 2026 (Q4 FY26), up 2.5% from ₹17 crore in the same quarter last year.

Net profit fell 5.4% year-on-year to ₹1 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹1.98.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 11.4%, compared with 10.0% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹38 crore with a net profit of ₹3 crore.

Valuation snapshot

At the current price of ₹87.00, 544143 has a market capitalisation of ₹47 crore and a trailing P/E of about 15.5.

Within the Medical Equipment & Supplies industry, it is the 10th-largest of the 13 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 62.24%, public shareholders 37.75% of Royal Sense Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹47 Cr

Current Price ?

₹87.0

P/E ?

15.46below ind

Industry P/E ?

26.90

P/B ?

1.40

P/S ?

1.23

P/FCF ?

258.58

Enterprise Value ?

₹56 Cr

EV/EBITDA ?

11.52

PEG ?

N/A

Earnings Yield ?

8.6%

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹38 Cr

OPM ?

12.8%

Profit after tax (TTM) ?

₹3 Cr

EPS (TTM) ?

₹5.63

ROCE ?

13.9%

ROE ?

9.1%

ROA ?

6.5%

Growth

Sales — latest qtr ?

₹17 Cr

PAT — latest qtr ?

₹1 Cr

YoY qtr sales growth ?

2.5%

YoY qtr profit growth ?

-5.4%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹9 Cr

Debt to Equity ?

0.27

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

62.24%

Change in promoter holding ?

-4.79%

Pledged percentage ?

N/A

Market

Return 3 months ?

-25.0%

Return 6 months ?

-43.0%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025	Mar 2026	YoY %	QoQ %
Sales	8	11	11	17	21	17	+2.5%	—
Operating Profit	1	1	3	2	3	2	+17.0%	—
Other Income	0	0	0	0	0	0	+20.0%	—
Interest	0	0	0	0	0	0	+214.3%	—
Depreciation	0	0	0	0	0	0	+200.0%	—
Profit Before Tax	1	1	3	2	3	2	-1.9%	—
Net Profit	1	1	2	1	2	1	-5.4%	—
EPS	2.03	2.04	3.94	2.25	3.64	1.98	-12.0%	—
OPM %	11.7%	13.1%	23.5%	10.0%	13.9%	11.4%	+14.0%	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 3 periods)

Metric	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	4.90	4.97	5.35	+7.6%
Reserves	13.44	19.60	27.83	+42.0%
Borrowings	1.60	3.26	8.98	+175.5%
Other Liabilities	0.94	3.02	3.95	+30.8%
Total Liabilities	20.88	30.85	46.11	+49.5%
Fixed Assets	0.05	1.65	1.82	+10.3%
CWIP	0.00	0.00	0.00	—
Investments	0.43	0.44	4.43	+906.8%
Other Assets	20.40	28.76	39.86	+38.6%
Total Assets	20.88	30.85	46.11	+49.5%

💧 Cash Flow (latest 2 periods)

Metric	Mar 2024	Mar 2025	% Chg
Cash from Operating Activity	-0.79	1.80	+327.8%
Cash from Investing Activity	-4.55	-11.07	-143.3%
Cash from Financing Activity	13.10	2.89	-77.9%
Net Cash Flow	7.77	-6.39	-182.2%
Free Cash Flow	-0.82	0.18	+122.0%
CFO/OP	-33%	58%	+275.8%

➗ Ratios (latest 3 periods)

Metric	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	90.48	117.79	149.29	+26.7%
Inventory Days	6.27	53.66	106.73	+98.9%
Days Payable	0.46	22.43	2.95	-86.8%
Cash Conversion Cycle	96.29	149.02	253.07	+69.8%
Working Capital Days	118.78	100.63	142.13	+41.2%
ROCE %	—	18.04%	13.89%	-23.0%

👥 Shareholding (latest 4 periods)

Metric	Mar 2025	May 2025	Sep 2025	Mar 2026	% Chg
Promoters	67.03%	62.24%	62.24%	62.24%	+0.0%
Public	32.96%	37.76%	37.76%	37.75%	-0.0%
No. of Shareholders	325	335	410	416	+1.5%

⚖️ Peer comparison

Industry: Medical Equipment & Supplies · 13 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	FISCHER Fischer Medical	₹33.50	2,293	85.2	367	24	12.3%	6.7%	178.6%	2051.4%	249.4%	-24.3%
2	TARSONS Tarsons Products	₹330.00	1,756	157.9	441	11	27.0%	2.5%	-66.3%	-81.4%	20.7%	-181.0%
3	DENTALKART Vasa Denticity	₹563.10	977	80.0	299	12	4.4%	4.0%	16.7%	-28.5%	12.9%	-2.9%
4	543916 Hemant Surgical	₹193.85	544	13.9	231	18	10.4%	7.8%	—	—	187.9%	160.0%
5	543363 Prevest Denpro	₹616.50	456	32.8	75	23	35.7%	29.9%	13.6%	17.6%	23.7%	24.8%
6	QMSMEDI QMS Medical	₹185.89	359	52.7	162	7	13.1%	4.1%	5.1%	-47.9%	23.7%	-0.8%
7	NURECA Nureca	₹331.55	331	75.9	153	4	2.7%	2.8%	34.0%	146.7%	18.0%	277.2%
8	530427 Choksi Asia	₹65.64	122	7.2	47	5	14.5%	11.1%	61.1%	173.2%	-22.5%	-10.1%
9	527005 Shree Pacetronix	₹168.25	55	19.2	21	3	24.8%	15.3%	28.7%	324.3%	-8.3%	14.5%
10	544143 Royal Sense	₹139.00	47	24.7	38	3	12.8%	8.0%	—	—	2.5%	-5.4%
11	533212 GKB Ophthalmics	₹104.90	32	17.6	150	6	7.0%	3.7%	36.8%	142.7%	2.3%	388.5%
12	531380 Centenial Surgical	₹110.90	27	—	56	-1	10.7%	-2.6%	0.6%	-38.1%	18.6%	1937.8%
13	542765 Transpact Enterprises	₹325.00	4	140.1	0	0	63.2%	47.4%	—	—	12.5%	-20.0%

❓ Frequently asked questions

What was Royal Sense Ltd's revenue in Q4 FY26?